Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Auteurs : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart-Gebhart M, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 559-569

FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.

Auteurs : De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Année : 2019
Journal : EBioMedicine
Volume : 39
Pages : 226-238

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Auteurs : Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber Rd, Coates AS, Goldhirsch A, Thürlimann B, Regan MM
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 105-114

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Auteurs : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Année : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.

Auteurs : Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Michael Dixon J, Piccart-Gebhart M, Sotiriou C
Année : 2019
Journal : PLoS One
Volume : 14
Pages : e0216175

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Auteurs : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588

Tumor dormancy at bedside: A late awakening.

Auteurs : Demicheli R, Desmedt C, Piccart-Gebhart M, Biganzoli E
Année : 2019
Journal : Breast
Volume : 45
Pages : 61-63

ESR1 mutations in metastatic lobular breast cancer patients.

Auteurs : Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, OLeary B, Van den Eynden G, Salgado R, Turner NC, Piccart-Gebhart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C
Année : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 9

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.

Auteurs : Caparica R, Lambertini M, Pondé N, Fumagalli D, de Azambuja E, Piccart-Gebhart M
Année : 2019
Journal : Ther Adv Med Oncol
Volume : 11
Pages : 1758835919827714

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.

Auteurs : Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Peña L, Izquierdo M, Huober J, Baselga J, Piccart-Gebhart M, De Braud FG, Apolone G, Verderio P, Daidone MG
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3887-3895

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.

Auteurs : Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, Tkint de Roodenbeke D, Willard-Gallo K
Année : 2019
Journal : Cancer Lett
Volume : 450
Pages : 88-97

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Auteurs : Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 1434

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Auteurs : Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F, + collaborators (among others :, Piccart-Gebhart M
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 371-382

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.

Auteurs : Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart-Gebhart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 336-349

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.

Auteurs : Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 361-370

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Auteurs : Sonnenblick A, Bailey A, Uziely B, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Cameron D, Bell R, Zardavas D, Al-Sakaff N, Gelber Rd, Dowsett M, Leyland-Jones B, Piccart-Gebhart M, de Azambuja E
Année : 2019
Journal : Anticancer Res
Volume : 39
Pages : 797-802

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?

Auteurs : Pondé N, Gelber Rd, Piccart-Gebhart M
Année : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 1

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.

Auteurs : Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M
Année : 2019
Journal : ESMO Open
Volume : 4
Pages : e000515

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Auteurs : Lambertini M, Campbell C, Gelber Rd, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart-Gebhart M, Loi S, de Azambuja E
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 177
Pages : 103-114

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

Auteurs : McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart-Gebhart M, Gradishar WJ, Chia S, Di Leo A, Malorni L
Année : 2019
Journal : Eur J Cancer
Volume : 114
Pages : 55-66